Fenofibrate

Fenofibrate is an oral lipid-lowering drug belonging to the fibrate class, agents used to correct abnormal blood fats ^[1]. It is prescribed chiefly to lower elevated triglycerides and to treat mixed dyslipidemia, in which both triglycerides and cholesterol are raised, and it tends to lower triglycerides and raise HDL cholesterol more than it lowers LDL cholesterol ^[1]. The drug is a prodrug: after it is swallowed it is converted to its active form, fenofibric acid, which is responsible for its effects ^[1].

Fenofibrate has been marketed under a number of brand names, including Tricor, Lipidil and Lofibra, and is also widely available as a generic ^[1]. It is frequently used alongside a statin when a statin alone does not adequately control triglycerides, and it remains a commonly prescribed lipid medication ^[1]. Because both drug classes can affect muscle, combining a fibrate with a statin calls for some caution ^[1].

Several large trials have tested whether fenofibrate reduces cardiovascular events. The FIELD study, in people with type 2 diabetes, did not significantly cut its primary measure of coronary events, although it reduced some secondary cardiovascular outcomes and slowed certain diabetic complications ^[2]. The ACCORD Lipid trial found that adding fenofibrate to a statin did not lower the overall rate of major cardiovascular events in high-risk diabetic patients, though analyses suggested a possible benefit in the subgroup with both high triglycerides and low HDL cholesterol ^[3]. Findings like these are why fenofibrate is generally reserved for managing high triglycerides rather than used as a routine partner to statins for everyone ^[1][3].

Fenofibrate is a prescription-only medicine. Its recognized side effects include headache, muscle aches and gastrointestinal upset, and less commonly gallstones or, rarely, muscle breakdown, particularly when it is combined with a statin ^[1].

Fenofibrate is prescription only. Common effects include stomach upset, headache, and reversible rises in liver enzymes, so liver tests are monitored. It can raise blood creatinine and, less often, cause gallstones because it increases cholesterol in bile. The most important interaction is with statins, since the pair can raise the risk of muscle injury and, rarely, rhabdomyolysis; gemfibrozil is riskier here than fenofibrate. It potentiates warfarin, so anticoagulation must be watched, and it needs dose separation from bile acid sequestrants. It is contraindicated in severe kidney disease, active liver disease, and gallbladder disease. Report unexplained muscle pain, weakness, or dark urine promptly.

Fenofibrate is frequently co-prescribed with statins for mixed dyslipidemia, and this combination carries a pharmacokinetic interaction. When fenofibrate is combined with simvastatin, the drugs interact; this is not considered clinically significant for lipid control, and large randomized trials (ACCORD Lipid and FIELD) found no increase in serious adverse events such as rhabdomyolysis ^[5]. Fenofibrate has minimal effect on atorvastatin exposure, with actual clinical studies confirming negligible atorvastatin interactions with fenofibrate ^[6]. This is a pharmacokinetic interaction mediated by changes in statin metabolism and transport.

Fenofibrate also increases serum creatinine and homocysteine levels but does not increase the risk of diabetic nephropathy or thrombotic events when combined with statins in large prospective trials ^[5]. The mechanism appears to involve renal hemodynamic effects rather than true drug-drug interaction at the metabolic level. Interactions with other lipid-lowering agents, most antihypertensives, and non-cardiovascular drugs remain poorly studied.

Checking a whole stack? Run it through interactions + stacks.

Fenofibrate belongs to the fibrate class and was developed in France by Groupe Fournier (Laboratoires Fournier) in the 1970s as a derivative of the earlier fibrate clofibrate. It was first marketed in France in 1975 and, after decades of European use, reached the United States market in 1998 under the brand name Tricor. Researchers later established that its active metabolite, fenofibric acid, works by activating the nuclear receptor PPAR-alpha to reshape the body's handling of fats. Two major cardiovascular trials in people with type 2 diabetes, FIELD in 2005 and ACCORD Lipid in 2010, tested it rigorously; while their primary cardiovascular endpoints were mixed, both unexpectedly signaled a slowing of diabetic retinopathy progression. That eye-protective finding has since driven renewed scientific interest and dedicated study of the drug beyond its lipid-lowering origins.

Fenofibrate holds a respected place in lipid management as a go-to agent for stubbornly high triglycerides and mixed dyslipidemia, where statins alone often fall short. Clinicians value its dual action, trimming triglyceride-rich particles while nudging up the protective HDL fraction, and it is frequently paired with a statin for broader lipid control. Its most intriguing modern chapter is the consistent signal across FIELD and ACCORD that it can slow diabetic retinopathy, an effect that appears largely independent of its lipid changes and has opened a genuinely new avenue of research. As a long-established generic taken once daily, it is both affordable and familiar to prescribers. It is fair to note that its cardiovascular event benefit is most convincing in patients with high triglycerides and low HDL rather than across the board.